Abstract
As emerging techniques continue to impact cancer genomics, precision oncology may be implemented in anticancer drug development if firmly grounded.
Novel mechanisms and novel concepts of cancer pathogenesis, such as cancer stem cells and cancer-derived induced pluripotent stem cells, provide new opportunities to model the cancer genome and may generate new avenues for anticancer drug development.
Drug combinations naturally fit for multiple cancer pathologies and tend to be the major anticancer drug development focus.
Gene editing is being tested in humans. In the near future, it may be applied to expand knowledge of cancer genomics and facilitate novel models in anticancer development.
Novel mechanisms and novel concepts of cancer pathogenesis, such as cancer stem cells and cancer-derived induced pluripotent stem cells, provide new opportunities to model the cancer genome and may generate new avenues for anticancer drug development.
Drug combinations naturally fit for multiple cancer pathologies and tend to be the major anticancer drug development focus.
Gene editing is being tested in humans. In the near future, it may be applied to expand knowledge of cancer genomics and facilitate novel models in anticancer development.
Original language | English |
---|---|
Pages (from-to) | 852-872 |
Number of pages | 21 |
Journal | Trends in Pharmacological Sciences |
Volume | 38 |
Issue number | 10 |
Early online date | 11 Jul 2017 |
DOIs | |
Publication status | Published - 1 Oct 2017 |